ArticleTumori2026

Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer.

Chiara Benvenuti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.